Cancer in the Endocrine Landscape
How the State of the Whole Organism Shapes Tumor Behavior
Table of Contents:
The Overview
Historically, oncology focused primarily on internal cellular mutations and local tumor dynamics. However, modern research reveals that tumors cannot be fully understood in isolation from the rest of the body. A tumor exists within a complex organism where metabolic, immune, neurological, and endocrine systems are constantly communicating. This organismal perspective expands traditional oncology by incorporating systemic physiological signals into tumor behavior.
The endocrine system functions as a major long-distance communication network connecting various tissues and organs. Hormones such as insulin, cortisol, sex hormones, and growth factors circulate throughout the body and regulate normal physiological activities. Cancer cells, stromal cells, and immune cells within tumors retain receptors and signaling pathways capable of responding to these circulating signals. Consequently, systemic endocrine physiology helps shape the selective environment in which malignancies develop and evolve.
While certain malignancies like breast and prostate cancers are classically recognized as hormone-sensitive, endocrine effects extend far beyond these traditional categories. Recent studies demonstrate meaningful hormonal influences in various other cancers, including melanoma, lung, gastric, and colorectal malignancies. Some cancers are directly endocrine-dependent, whereas a much larger group is endocrine-modulated by hormonal conditions influencing their overall behavior. Recognizing this distinction blurs the rigid boundary between traditional hormonal and non-hormonal cancers.
Research increasingly uncovers unexpected hormonal influences in cancers not traditionally considered endocrine-dependent. For instance, androgen-receptor signaling has been shown to increase melanoma invasiveness through enhanced cellular adhesion and migration. Similarly, estrogen-receptor beta activity in lung adenocarcinoma promotes lymph-node metastasis by recruiting tumor-associated neutrophils that facilitate lymphatic vessel formation. These findings illustrate how classical hormone receptors and signaling pathways actively participate in metastatic behaviors across diverse cancer types.
Stress hormones released during sustained physiological or psychological challenges significantly alter the metastatic microenvironment. Activation of the hypothalamic-pituitary-adrenal axis and sympathetic nervous system leads to the secretion of cortisol, epinephrine, and norepinephrine. Experimental studies demonstrate that chronic stress can increase lung metastasis by altering neutrophils and forming neutrophil extracellular traps that make tissues more receptive to cancer cells. Thus, neuroendocrine signaling driven by stress physiology can bridge brain activity and distant tissue modification to promote cancer spread.
Metabolic processes and chronic signaling states profoundly influence the environment in which malignant cells compete and evolve. Insulin and insulin-like growth factors regulate metabolism and cell growth, overlapping with major survival pathways frequently altered in cancer. Epidemiological studies link insulin resistance and hyperinsulinemia with increased risks for several cancers, representing a distinct physiological state rather than a mere laboratory value. This systemic metabolic context helps determine whether premalignant and malignant cell populations successfully expand.
Adipose tissue acts as an active endocrine and immunological organ rather than a passive energy storage depot. It releases leptin, adiponectin, inflammatory mediators, and lipids while participating directly in sex-hormone metabolism through enzymes like aromatase. Adipocytes and associated immune cells create a biologically active environment that alters cancer metabolism, inflammation, and invasive behavior. Consequently, obesity-related cancer risks are driven by complex systemic biological messages involving adipose dysfunction and chronic low-grade inflammation.
The biological environment surrounding a tumor changes dynamically across the twenty-four-hour circadian cycle. Circadian rhythms regulate cortisol secretion, melatonin production, insulin sensitivity, immune trafficking, and DNA repair processes. Research shows that circulating tumor cells and their metastatic potential can exhibit temporal organization influenced by daily hormonal fluctuations. Recognizing circadian biology highlights that a tumor experiences different metabolic and immunological conditions depending on the time of day.
Modern oncology is moving toward an integrated model that connects genetic, metabolic, immunological, and organismal perspectives. Hormones, nervous system signaling, and circadian rhythms provide the communication networks linking these diverse layers of cancer biology. Clinically, this framework points toward precision endocrine oncology, where therapies target specific functional endocrine dependencies rather than relying on broad hormonal manipulations. Ultimately, viewing cancer as an evolving system embedded within the human body offers a more complete understanding of the disease.
Introduction
For much of the modern history of oncology, cancer has been understood primarily as a disease arising within individual cells. A cell acquires genetic or epigenetic alterations that allow it to escape normal controls on growth, resist signals that would ordinarily cause it to stop dividing or die, evade immune surveillance, and eventually acquire the ability to invade surrounding tissues and spread to other parts of the body. This understanding has been extraordinarily productive. It has given us oncogenes, tumor-suppressor genes, molecular profiling, targeted therapies, and an increasingly precise understanding of the machinery operating within malignant cells. Yet as cancer research has matured, it has also become increasingly clear that the cancer cell cannot be understood fully in isolation. A tumor exists inside a tissue, that tissue exists inside an organ, and that organ exists within an organism whose metabolic, immune, neurological and endocrine systems are continuously communicating with one another.
This broader perspective has already transformed the way researchers think about the tumor microenvironment. Tumors are no longer viewed simply as masses of malignant cells. They contain fibroblasts, immune cells, blood vessels, extracellular matrix, inflammatory mediators and numerous other components that can either restrain or support cancer. Increasingly, however, even the concept of the local tumor microenvironment appears incomplete. The cells within a tumor are continually exposed to signals arriving from elsewhere in the body. Insulin reflects nutrient availability. Cortisol and catecholamines communicate physiological demand and stress. Sex hormones influence growth, differentiation and tissue behavior. Adipose tissue produces hormones and inflammatory mediators. Circadian signals alter metabolism, immunity and cellular repair across the twenty-four-hour day. Growth factors help coordinate development, tissue maintenance and regeneration. These signals circulate throughout the body, and cancer cells, stromal cells and immune cells within tumors remain capable of responding to them.
This leads toward a broader way of understanding cancer that may become increasingly important over the coming years. The physiological state of the whole organism may be part of the selective environment in which cancer develops and evolves. Hormones are especially important within this framework because they are among the body’s primary long-distance communication systems. They allow one part of the organism to alter the behavior of cells located elsewhere. If cancer cells or the tissues surrounding them are able to make use of those signals, endocrine physiology can become part of the environment that determines which malignant cells survive, which become invasive, which escape immunity, and which are able to establish themselves in distant organs.
Traditionally, the phrase “hormone-sensitive cancer” has been reserved for a relatively small group of malignancies. Estrogen and progesterone signaling are central to many breast cancers. Androgen signaling is fundamental to prostate cancer. Hormonal influences are also well established in portions of endometrial, ovarian and several other cancers. What is changing is not the importance of those familiar examples, but the recognition that endocrine effects may extend far beyond them. Recent studies have identified meaningful hormonal influences in melanoma, lung cancer, gastric cancer, pancreatic cancer, colorectal cancer and other malignancies that would rarely be described clinically as hormone-dependent. In some cases the hormone acts directly on the cancer cell. In others, perhaps even more interestingly, it changes fibroblasts, immune cells, lymphatic vessels, blood vessels or the tissues into which cancer is attempting to spread.
The distinction may ultimately prove useful. Some cancers are clearly endocrine-dependent: interrupting a particular hormone-receptor pathway can dramatically slow their growth. A much larger group of cancers may instead be endocrine-modulated. Their existence may not depend upon a particular hormone, yet hormonal conditions can still influence their behavior. Once this distinction is recognized, the boundary between “hormonal” and “non-hormonal” cancer begins to look less absolute.
The Body as a Signaling Environment
One of the most useful ways to understand this emerging perspective is to think of the endocrine system as a communication network. The endocrine glands do not simply release isolated chemicals into the bloodstream. They help coordinate the behavior of distant tissues so that the body functions as a unified organism. The brain and pituitary communicate with the thyroid, adrenal glands, ovaries and testes. The pancreas continually adjusts insulin and glucagon according to changing nutrient conditions. Adipose tissue informs the rest of the body about energy storage and metabolic state. The adrenal glands help organize physiological responses to challenge. Growth hormone and IGF signaling respond to age, nutritional status, sleep and other aspects of physiology.
Normal cells require this information. A liver cell behaves differently after a meal than during an overnight fast. Muscle changes its handling of glucose and fatty acids according to activity and insulin signaling. Bone responds to mechanical stress, sex hormones and mineral-regulating hormones. Immune cells alter their function in response to glucocorticoids and adrenergic signals. Reproductive tissues respond dramatically to changing endocrine conditions.
Cancer cells do not suddenly become disconnected from these systems. Their responses may become abnormal, exaggerated or opportunistic, but they remain biological cells equipped with receptors, signaling pathways and transcriptional machinery capable of interpreting their environment. In some tumors, a receptor may be overexpressed. In others, downstream signaling may be altered so that a normal physiological signal produces an abnormal effect. In still others, the malignant cell itself may not be the primary target of the hormone at all. The relevant receptor may reside on a fibroblast, macrophage, neutrophil or endothelial cell that subsequently changes the conditions surrounding the tumor.
This is where endocrine biology begins to intersect with cancer evolution. Tumors are heterogeneous populations. Different malignant cells within the same tumor may contain different mutations, epigenetic states, metabolic strategies and signaling capacities. Those differences matter because cancer development is not simply a process of accumulating abnormalities. It is also a process of selection. Cells possessing characteristics that are advantageous within a particular environment are more likely to survive and expand.
The environment within a tumor can select for cells that tolerate low oxygen, resist immune attack or survive chemotherapy. The same logic can be extended to systemic signals. If one population of cancer cells can use insulin or IGF signaling more effectively than another, a metabolically favorable environment may give that population an advantage. If androgen-receptor signaling increases the invasive capacity of a melanoma cell, endocrine conditions can influence which cells are best able to spread. If glucocorticoid signaling makes a cancer cell less visible to the immune system, that pathway may contribute to selection for immune escape.
This does not mean that hormones should be understood as a new universal cause of cancer. Cancer rarely has a single cause. Genetic instability, epigenetic alterations, carcinogenic exposures, chronic inflammation, aging, metabolism, tissue injury, immune surveillance and chance all interact in complicated ways. The endocrine system is better understood as one of the major environments through which those processes are shaped. It may not determine which mutations occur, but it can influence the consequences of those mutations and therefore help determine which cellular populations become successful.
What Recent Research Is Beginning to Reveal
Melanoma offers an instructive example because it has never been categorized in the same way as breast or prostate cancer. Recent experimental work, however, has found that androgen-receptor signaling can increase melanoma invasiveness. In one study, androgen signaling increased expression of FUT4, an enzyme involved in fucosylation, a process that modifies proteins and can alter their behavior. Through effects on adhesion-related proteins, including L1CAM, this signaling increased the ability of melanoma cells to detach, migrate and invade. Other recent work has suggested that androgen-receptor activity may also influence how effectively melanoma cells evade natural-killer-cell attack.
The clinical implications remain uncertain, and it would be premature to assume that androgen blockade should become a routine treatment for melanoma. The biological implication is nevertheless important. A classical steroid-hormone receptor is participating in the metastatic behavior of a cancer that is not traditionally considered hormonal. This is precisely the kind of observation that challenges the older binary classification of cancers as hormone-sensitive or hormone-insensitive.
Lung adenocarcinoma provides another example in which the endocrine effect appears to extend beyond the malignant cell itself. Recent research has linked estrogen-receptor beta activity with lymph-node metastasis through a pathway involving tumor-associated neutrophils and lymphatic vessels. Estrogen-receptor signaling increased production of CCL15, which helped recruit neutrophils into the tumor environment. Those neutrophils in turn produced VEGF-C, a major regulator of lymphatic-vessel formation. The result was a microenvironment more capable of supporting lymphatic dissemination.
This is an important illustration of how hormonal signaling can become distributed across several different cell types. Estrogen does not simply enter a cancer cell and cause it to divide. Hormonal signaling changes communication between cancer cells, immune cells and the lymphatic system. The ultimate biological effect-greater metastatic potential-emerges from the interaction of the whole network.
An especially striking example comes from research on gastric cancers that spread to the ovary. Ovarian metastases from stomach cancer have long been recognized clinically, particularly in younger women, but newer research has begun to clarify why the ovary may sometimes provide unusually favorable conditions for these cancer cells. Investigators studying the ovarian metastatic environment identified estrogen-responsive fibroblasts capable of producing midkine, a signaling molecule that promoted migration and invasion in gastric cancer cells. The same signaling environment also influenced macrophages in ways that could make the metastatic niche more permissive.
The significance of this finding goes well beyond gastric cancer. It suggests that the hormonal characteristics of a destination organ may help determine whether disseminated cancer cells are able to colonize it. The metastatic cell carries one set of biological properties, but the organ into which it arrives carries another. Estrogen-responsive ovarian fibroblasts can alter the “soil” in which the metastatic “seed” attempts to grow.
More than a century after Stephen Paget proposed the seed-and-soil theory of metastasis, this work suggests that the soil itself may have an endocrine dimension. Bone, liver, lung, brain, adrenal tissue, ovary and other common metastatic sites differ not only in blood supply and extracellular matrix but also in metabolism, immune composition and hormonal responsiveness. A circulating cancer cell therefore enters an environment whose characteristics are continually being shaped by the physiology of the entire body.
Stress Physiology and the Metastatic Environment
The interaction between cancer and stress hormones provides one of the clearest examples of long-distance signaling between the organism and the tumor. When the brain perceives sustained physiological or psychological challenge, it can activate the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system. Cortisol, epinephrine and norepinephrine then help coordinate changes throughout the body, altering metabolism, circulation, immune activity and energy allocation.
Cancer cells and the tissues surrounding them are exposed to those same signals.
A particularly revealing experimental study of breast cancer found that chronic stress substantially increased lung metastasis in mice. The mechanism was not simply that the primary tumor grew faster. Glucocorticoid signaling altered neutrophils and increased their tendency to form neutrophil extracellular traps, commonly called NETs. These structures normally play a role in antimicrobial defense, but in this setting they helped remodel the lung environment. Fibronectin increased, immune-cell composition changed, and the lungs became more receptive to metastatic cells. When neutrophils were removed or NET formation was disrupted, much of the stress-associated increase in metastasis disappeared.
The larger significance lies in the sequence of events. A signal originating in the brain altered adrenal physiology. Adrenal hormones affected immune cells. Those immune cells traveled to the lung and changed the characteristics of the tissue. The altered lung environment then changed the probability that disseminated cancer cells would successfully establish metastases. The biology therefore crossed several organ systems before influencing the final metastatic outcome.
This is a good example of why statements such as “stress causes cancer” are both scientifically inadequate and unnecessarily alarming. The evidence supports something much more specific and more interesting. Neuroendocrine signaling can alter immunity and tissue environments in ways that affect cancer biology under certain conditions. Whether that influence is large or small in any individual person will depend upon many interacting variables.
Glucocorticoids themselves illustrate the complexity particularly well. In pancreatic cancer models, glucocorticoid-receptor signaling has been shown to increase PD-L1 expression while reducing MHC class I expression. Because MHC-I helps cytotoxic T cells recognize abnormal cells and PD-L1 helps inhibit activated T cells, the combined effect can make malignant cells less visible to immune attack. Experimental inhibition of glucocorticoid signaling improved immune recognition in some models.
Yet glucocorticoid signaling is not universally cancer-promoting. Other research has found circumstances in which activation of the glucocorticoid receptor can increase sensitivity to endocrine therapy in estrogen-receptor-positive breast cancer. The direction of the effect depends on the cancer, the receptor state, the surrounding signaling network and the therapeutic context.
This context dependence may ultimately prove to be one of the most important lessons of endocrine oncology. A hormone cannot usually be classified simply as favorable or unfavorable. The biological effect of estrogen, testosterone, cortisol or insulin depends upon which cells receive the signal, which receptor subtypes are present, what genetic alterations exist downstream, what the immune and metabolic environments look like, and at what stage of the disease the signaling occurs.
Metabolism as Endocrine Communication
The broader endocrine perspective becomes even more interesting when insulin and the insulin-like growth factor system are included. Insulin is usually described as a metabolic hormone because of its role in controlling glucose and nutrient storage, but metabolism and cellular growth are deeply interconnected. Insulin signaling overlaps with major growth and survival pathways such as PI3K, AKT and mTOR, all of which are frequently altered in cancer.
The important point is not that insulin is intrinsically carcinogenic. The more useful question is whether chronic metabolic signaling can change the environment in which premalignant and malignant cells compete. A cell carrying a particular mutation may behave one way in an insulin-sensitive, metabolically flexible environment and another in a state of chronic insulin resistance and compensatory hyperinsulinemia.
Large epidemiological studies have continued to strengthen associations between insulin resistance and several forms of cancer, including cancers of the uterus, kidney, pancreas, colon and breast. Such studies cannot establish simple causation because insulin resistance travels with many other biological changes, including inflammation, altered adipokines, changes in sex-hormone metabolism and differences in body composition. Yet this is precisely why the systemic perspective may be more useful. Insulin resistance is not merely an elevated laboratory value. It represents a different physiological state of the organism.
IGF signaling fits naturally within the same framework. Insulin-like growth factors help regulate growth, tissue repair and cellular survival. Higher circulating IGF-I has been associated with increased risk for several cancers, with some of the strongest evidence involving prostate, breast and colorectal cancer. Again, the relationship is not uniform across every tissue, but it reinforces the idea that pathways involved in normal growth regulation can become relevant when malignant cells learn to exploit them.
The history of IGF-targeted therapies also provides an instructive lesson. Early enthusiasm led to attempts to block IGF signaling broadly in cancer, but many trials were disappointing. This was sometimes interpreted as evidence that the pathway was not important. More recent work suggests another possibility: only particular molecular subgroups may be strongly dependent upon the pathway. When a treatment is given to a biologically mixed population, a substantial effect in a small subgroup can disappear statistically within the larger trial.
This is likely to become increasingly relevant as endocrine oncology develops. The important question may not be whether insulin, IGF, estrogen or androgen signaling matters to a named cancer in general, but whether a particular tumor is functionally dependent upon that pathway.
Adipose Tissue, Inflammation and the Endocrine State
The role of adipose tissue further expands the picture. Body fat was once viewed primarily as a passive storage depot for energy. It is now recognized as an active endocrine and immunological organ that releases leptin, adiponectin, inflammatory mediators, lipids and many other signals. Adipose tissue also participates in sex-hormone metabolism through enzymes such as aromatase.
Cancer developing near or within adipose tissue therefore encounters a biologically active environment. Adipocytes and adipose-associated immune cells can alter cancer-cell metabolism, inflammatory signaling, blood-vessel formation and invasive behavior. In some cancers, nearby adipocytes can even provide fatty acids that malignant cells use as fuel or as building blocks for membranes.
This helps explain why the relationship between obesity and cancer is more complicated than the number on a scale. Two people with similar body weight can differ substantially in visceral fat, insulin sensitivity, inflammatory state, sex-hormone metabolism and adipokine production. From the perspective of cancer biology, those differences may matter more than body mass itself.
The systemic question therefore becomes less about weight in isolation and more about the biological messages being generated by metabolic tissues. Adipose dysfunction, insulin resistance, chronic low-grade inflammation and altered endocrine signaling often occur together. They create a physiological environment that differs from that of metabolically healthy tissue.
Hormonal Influences May Begin Before Cancer Is Visible
One of the most important implications of this perspective is that endocrine signaling may shape the biological landscape before a recognizable tumor ever exists. Cancer generally develops over many years. During that time, tissues undergo continuous cycles of cellular renewal, repair, immune surveillance and adaptation. Cells accumulate genetic and epigenetic abnormalities, some of which disappear and others of which persist.
Hormones influence these normal tissues throughout the entire process.
Recent work in women at increased risk of breast cancer has provided a particularly interesting illustration. Researchers studying the effects of blocking progesterone signaling found that anti-progestin treatment altered populations of luminal progenitor cells within breast tissue and changed other characteristics associated with susceptibility to malignant transformation. These studies do not establish that progesterone blockade prevents breast cancer, but they demonstrate that changing a hormonal signal can alter the composition of tissue before cancer develops.
That observation has larger significance. If endocrine conditions influence which progenitor-cell populations expand, how often they divide, how inflammatory or fibrotic the tissue becomes, or how effectively abnormal cells are removed, then hormonal physiology becomes part of the terrain in which cancer begins.
The same principle can apply to inherited genetic vulnerability. BRCA1 provides one example. A person who inherits a defective copy of BRCA1 still begins life with another functioning copy. Cancer generally requires additional molecular events before the remaining protective function is lost. Experimental work has suggested that estrogen and certain estrogen metabolites can increase replication stress and DNA damage in BRCA1-vulnerable mammary cells. This does not mean that estrogen alone creates BRCA-associated cancer. It means that genetic susceptibility and endocrine conditions can interact.
Genes establish possibilities, but physiology helps determine how those possibilities are expressed.
That is a more useful model than either genetic determinism or the opposite assumption that cancer is simply a consequence of lifestyle or environment. The genome matters, and the organism matters. Cancer develops through their interaction.
Circadian Biology: The Endocrine Environment Changes with Time
Hormonal signaling also introduces another dimension that is sometimes overlooked: the biological environment of a tumor changes across the twenty-four-hour day. Cortisol follows a strong circadian rhythm. Melatonin rises during darkness. Insulin sensitivity changes with time of day. Immune-cell trafficking, body temperature, sympathetic activity, liver metabolism and DNA-repair processes all show circadian organization.
A tumor therefore does not live in a static endocrine environment. The molecular conditions surrounding it in the middle of the night can differ significantly from those present during the afternoon.
This became particularly evident in research on circulating tumor cells in breast cancer. Investigators found that the release of cancer cells into the bloodstream was not uniform across the day. In both patients and experimental models, substantially more circulating tumor cells appeared during the resting phase. In experimental systems, those cells also showed greater metastatic potential. Hormonal signals including melatonin, glucocorticoids, testosterone and insulin were implicated in regulating aspects of this daily pattern.
The discovery was surprising because it suggested that metastatic dissemination itself can have circadian organization. The tumor is participating, albeit abnormally, in the temporal physiology of the organism.
Other experimental work has shown that chronic disruption of normal circadian rhythms can increase metastatic behavior and alter the immune characteristics of tumors. This remains an active area of investigation, and it would be premature to reduce the findings to simple prescriptions about sleep. Their deeper significance is that time is another component of the tumor’s environment. The same cancer may experience different metabolic, hormonal and immune conditions at different hours.
The body at three in the morning is not biologically identical to the body at three in the afternoon. Cancer cells appear capable of sensing at least some of that difference.
The Nervous, Endocrine and Immune Systems Increasingly Appear as One Network
The emerging field sometimes called cancer neuroscience further blurs the traditional boundaries between organ systems. The sympathetic nervous system influences tissues directly through local nerve fibers and indirectly through catecholamines released from the adrenal glands. Tumor cells, fibroblasts and immune cells can all express adrenergic receptors.
Experimental studies have found beta-adrenergic signaling influencing metastasis and immune suppression in several models. In some circumstances, blocking beta-adrenergic receptors has increased T-cell activity within tumors and improved responses to immunotherapy. Other research has identified adrenergic pathways capable of stimulating tumor-promoting transcriptional programs.
Again, none of this establishes a simple psychological model of cancer. Emotional states do not dictate the development of malignancy. What the research does show is that the nervous system communicates biochemically with peripheral tissues and that cancer cells can become participants in that communication.
This becomes especially significant because the endocrine, nervous and immune systems interact continuously. Cortisol changes immune-cell behavior. Adrenergic signals affect T cells, macrophages and natural killer cells. Immune inflammation changes neural and endocrine function in return. The body therefore does not contain separate systems operating independently. It contains interacting regulatory networks.
Cancer exists within those networks.
Metastatic Dormancy and Changes in the Organism
The concept of the organism as part of the tumor environment may be especially relevant to metastatic dormancy. One of the most puzzling aspects of cancer is the ability of disseminated cells to remain clinically silent in distant organs for years or occasionally decades before beginning to grow again.
The cancer cells themselves clearly matter, but increasing evidence suggests that changes in the surrounding tissue can determine whether dormant cells remain constrained or become active. Inflammation, aging, immune changes, tissue injury and extracellular-matrix remodeling have all been implicated in this process.
A particularly striking recent example came from experimental studies showing that respiratory viral infections could awaken dormant breast-cancer cells in the lungs. The inflammatory environment created by infection altered pulmonary tissue sufficiently that previously quiescent malignant cells began proliferating. Human observational data have raised similar questions, although they cannot establish the same mechanism.
This is not primarily a hormonal finding, but it is extremely relevant to the broader argument. The tumor cell had not necessarily undergone a dramatic new genetic transformation. The environment around it changed. A cell that had been biologically unsuccessful under one set of conditions became successful under another.
That is the essence of selection.
And it suggests that cancer recurrence may sometimes reflect changes not only in the tumor but also in the organism in which dormant cells reside.
Why This Perspective Does Not Reduce Cancer to Lifestyle
Any discussion of whole-body influences on cancer requires care because the subject has historically been handled poorly. Earlier theories sometimes suggested that cancer resulted from a particular personality, unresolved emotions or insufficient positive thinking. Such claims were scientifically weak and placed an unjustified burden on people already dealing with serious disease.
The emerging endocrine and systems biology of cancer is quite different.
It does not say that thoughts create tumors or that people can control cancer through attitude. It says that the nervous, endocrine, metabolic and immune systems generate measurable physiological signals and that tumors can respond to those signals.
Those are biological propositions that can be studied experimentally.
A stressful event may activate the HPA axis, but two people exposed to the same event can have very different physiological responses. Cortisol signaling may influence a particular cancer under one set of circumstances and have little relevance under another. Exercise, fasting, sleep, aging, infection and metabolic disease all alter systemic physiology, but none of them act through a single uniform pathway.
The useful conclusion is therefore not that individuals should somehow perfect their internal environment. It is that cancer biology extends beyond the tumor.
A More Integrated Model of Cancer
Seen in this way, endocrine biology does not compete with the genetic model of cancer, nor does it replace metabolic, immune or microenvironmental theories. It helps connect them.
Genetic alterations establish what a malignant cell is capable of doing. Epigenetic programs influence which genes are available for use. Metabolism determines how cells obtain and use energy and molecular building materials. The immune system determines which abnormal cells are eliminated and which escape surveillance. The local microenvironment provides physical structure, nutrients, oxygen, inflammatory signals and neighboring cells.
The endocrine and nervous systems add information about the state of the organism itself.
Those layers continually interact. Insulin signaling may matter greatly in a cell whose PI3K pathway is already altered. A glucocorticoid signal may become important in a tumor that is close to escaping immune surveillance. Estrogen may alter fibroblasts in one organ and cancer cells directly in another. Adrenergic signaling may change immune-cell function in ways that influence whether a metastasis succeeds. Circadian disruption may alter hormone secretion, metabolism and immune activity simultaneously.
This integrated model moves us away from asking which theory of cancer is correct. Cancer is genetic, metabolic, immunological, ecological and evolutionary at the same time. Endocrine signaling provides one of the major systems through which these different levels communicate.
From the Tumor Microenvironment to the Organismal Environment
Cancer research has already gone through one major conceptual expansion. Investigators once concentrated almost entirely on the malignant cell. They then recognized that fibroblasts, immune cells, blood vessels and extracellular matrix surrounding the tumor were active participants in disease. The tumor microenvironment became central to modern oncology.
The next expansion may be from the tumor microenvironment to what might reasonably be called the organismal environment.
The bloodstream passing through a tumor contains nutrients generated by digestion and liver metabolism. It contains hormones secreted by distant glands. Immune cells arrive from bone marrow, lymph nodes and spleen. Neural activity influences blood flow, immunity and local tissue behavior. Adipose tissue releases metabolic and inflammatory signals. Circadian systems organize these processes according to time of day.
The tumor is therefore not biologically sealed off from the rest of the body. It is continually sampling information about the organism.
What makes endocrine signaling particularly important is that long-distance coordination is exactly what hormones evolved to accomplish. They allow events occurring in one location to change the behavior of cells elsewhere. A tumor capable of exploiting those messages gains access to information that was never intended for malignant purposes but can nevertheless be used to support survival, growth or dissemination.
This may help bring together a number of findings that otherwise appear unrelated. The association of metabolic disease with particular cancers, the influence of sex and reproductive state, the effects of stress physiology on metastatic niches, the impact of circadian disruption, the role of adipose tissue, and the organ-specific nature of metastasis may all reflect different aspects of the same general principle.
The physiology of the organism contributes to the environment in which cancer evolves.
What This May Eventually Mean Clinically
The clinical implications of this idea are potentially substantial, although the maturity of the evidence differs considerably from one area to another. Endocrine therapy in breast and prostate cancer is already among the most successful examples of targeted therapy in oncology. Outside those diseases, much of the newer work remains preclinical or translational.
The most likely future is therefore not broad hormonal manipulation, but more precise identification of endocrine dependencies.
Instead of asking whether melanoma as a disease is androgen-sensitive, researchers may ask whether a particular patient’s melanoma shows strong functional androgen-receptor signaling. Rather than asking whether all lung adenocarcinomas are influenced by estrogen, it may become possible to identify tumors in which ER-beta signaling is actively orchestrating neutrophil recruitment and lymphatic spread. Pancreatic cancers may eventually be divided according to whether glucocorticoid-receptor signaling meaningfully contributes to immune escape.
This would represent a form of precision endocrine oncology.
It would also require looking beyond the malignant cell. Tumor profiling may increasingly need to characterize immune cells, fibroblasts and other elements of the microenvironment, as well as the receptors expressed on cancer cells themselves. Single-cell sequencing and spatial transcriptomics are beginning to make this type of analysis possible.
The result may eventually be a much more detailed map of endocrine activity within tumors: which cells are receiving hormonal signals, which genes become active in response, whether the same pathways operate in primary and metastatic sites, and whether those pathways can be altered therapeutically.
Toward a More Complete Understanding of the Person with Cancer
Perhaps the deepest value of this perspective is not that it gives us another list of therapeutic targets. Its value is that it changes where we draw the boundaries of cancer biology.
A tumor is an evolving population of abnormal cells, but those cells do not evolve in isolation. They exist within tissues shaped by age, metabolism, immunity, endocrine state, circadian organization, inflammation and nervous-system signaling. Those systemic conditions do not determine the cancer in a simple or deterministic way, but they help define the environment in which malignant cells compete.
A mutation may provide a new capability, but whether that capability proves useful depends upon the environment. A cell capable of using an abundant growth signal may expand when that signal is present. A cell able to resist immune attack may become dominant when immune pressure increases. A disseminated cancer cell may remain dormant for years until changes in the surrounding tissue make growth possible.
Cancer therefore unfolds through an ongoing dialogue between what the malignant cell is capable of doing and the conditions in which it must survive.
Hormones are among the major carriers of that dialogue because they convey information across long distances. The pancreas communicates metabolic abundance. Adipose tissue communicates energy reserves and inflammatory state. The adrenal glands communicate physiological demand. The gonads communicate reproductive and developmental information. The brain and circadian system help organize time. The immune system responds to all of these signals and in turn alters the tissues through which cancer must move.
The tumor is listening to this conversation molecularly, whether or not it was ever intended to participate in it.
This may ultimately be the most important implication of the emerging research. The significance of hormones in cancer is not simply that researchers are discovering a few additional tumors that respond to estrogen, androgen or cortisol. The larger realization is that endocrine signaling provides one of the mechanisms through which the condition of the whole organism becomes biologically relevant to the tumor.
That perspective does not diminish the importance of mutations. It does not deny the role of carcinogens, inherited susceptibility or chance. It does not turn cancer into a disease that can be controlled by lifestyle alone. Instead, it places all of these influences within a larger biological framework.
The cancer cell matters profoundly. The local tumor microenvironment matters profoundly. Increasingly, however, we also have to recognize that the organism matters.
Cancer is an evolving biological system embedded within another highly dynamic biological system: the human body. Understanding the communication between those two systems may become one of the most productive directions in cancer research, not because it replaces what we already know, but because it helps connect the many pieces into a more complete picture.